Search results for "EMT"

showing 10 items of 413 documents

Azimuthally-differential pion femtoscopy relative to the third harmonic event plane in Pb–Pb collisions at √sNN = 2.76 TeV

2018

Azimuthally-differential femtoscopic measurements, being sensitive to spatio-temporal characteristics of the source as well as to the collective velocity fields at freeze out, provide very important information on the nature and dynamics of the system evolution. While the HBT radii oscillations relative to the second harmonic event plane measured recently reflect mostly the spatial geometry of the source, model studies have shown that the HBT radii oscillations relative to the third harmonic event plane are predominantly defined by the velocity fields. In this Letter, we present the first results on azimuthally-differential pion femtoscopy relative to the third harmonic event plane as a fun…

Nuclear and High Energy PhysicsAzimuthally-differential femtoscopic measurementsheavy-ion collisionshiukkasfysiikkaNuclear Experiment
researchProduct

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective …

2017

Abstract Introduction:Even in the era of novel targeted therapies for the treatment of Chronic Lymphocytic Leukemia (CLL) patients, such as BTK, PI3K and BCL2 inhibitors, allogeneic hematopoietic stem cell transplantations (alloHCT) will remain an important treatment option for a subset of patients with very high risk CLL. The current study focused on the impact of center and procedure-related factors on outcomes after alloHCT, taking into account the impact of patient- and disease-related risk factors. Patients and Methods:Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analyzed. Their data were collected as part of the EBMT CLL Data Quality Initiative. Out…

OncologyMaleTransplantation ConditioningCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Chronic lymphocytic leukemiaMedizinQUALITY MANAGEMENT-SYSTEMKaplan-Meier Estimaterisk factor analysisGUIDELINESBiochemistryallogeneic stem cell transplantation; centre effects; chronic lymphocytic leukaemia; frailties; risk factor analysiscentre effectsTransplantation Conditioning / methods0302 clinical medicineRecurrenceRisk Factorsallogeneic stem cell transplantationLeukemia Lymphocytic Chronic B-Cell / mortalityRegistriesDelivery of Health Care / statistics & numerical dataIBRUTINIBddc:6160303 health sciencesALEMTUZUMABHazard ratioHematopoietic Stem Cell TransplantationProfessional PracticeHematologyMiddle Aged3. Good healthEurope030220 oncology & carcinogenesisABT-199CohortSURVIVALAlemtuzumabFemaleEurope / epidemiologymedicine.drugAdultmedicine.medical_specialtyAllogeneic transplantationImmunologyLower riskDIAGNOSISSettore MED/01 - Statistica Medica03 medical and health sciencesLeukemia Lymphocytic Chronic B-Cell / therapyHematopoietic Stem Cell Transplantation / methodsInternal medicinemedicineHumansKarnofsky Performance Status030304 developmental biologyAgedRetrospective Studiesbusiness.industryProportional hazards modelCHRONIC LYMPHOCYTIC-LEUKEMIARetrospective cohort studySTEM-CELL TRANSPLANTATIONCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryProfessional Practice / statistics & numerical dataTransplantationbusinessDelivery of Health Carefrailtieschronic lymphocytic leukaemia030215 immunologyRESPONSES
researchProduct

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neo…

2011

Summary Background Studies with pertuzumab, a novel anti-HER2 antibody, show improved efficacy when combined with the established HER2-directed antibody trastuzumab in breast cancer therapy. We investigated the combination of pertuzumab or trastuzumab, or both, with docetaxel and the combination of pertuzumab and trastuzumab without chemotherapy in the neoadjuvant setting. Methods In this multicentre, open-label, phase 2 study, treatment-naive women with HER2-positive breast cancer were randomly assigned (1:1:1:1) centrally and stratified by operable, locally advanced, and inflammatory breast cancer, and by hormone receptor expression to receive four neoadjuvant cycles of: trastuzumab (8 mg…

OncologyTime FactorsReceptor ErbB-2medicine.medical_treatmentDocetaxelchemistry.chemical_compoundTrastuzumabAntineoplastic Combined Chemotherapy Protocolsskin and connective tissue diseasesMastectomyNeoadjuvant therapyAged 80 and overeducation.field_of_studyMiddle AgedNeoadjuvant TherapyEuropeTreatment OutcomeOncologyDocetaxelChemotherapy AdjuvantFemaleTaxoidsPertuzumabBrazilmedicine.drugAdultCanadamedicine.medical_specialtyAsiaPopulationBreast NeoplasmsAntibodies Monoclonal HumanizedYoung AdultBreast cancerInternal medicineBiomarkers TumormedicineHumansNeoplasm InvasivenesseducationProtein Kinase InhibitorsneoplasmsAgedInflammationChemotherapybusiness.industryTrastuzumabmedicine.diseasechemistryTrastuzumab emtansinebusinessThe Lancet Oncology
researchProduct

The Role of Gemtuzumab Ozogamicin in Elderly AML Patients in Complete Remission.

2007

Abstract The majority of patients (pts) with acute myeloid leukemia (AML) are diagnosed in their 6th and 7th decade of life. AML in elderly pts is associated with poor response to conventional chemotherapy and limited long-term survival, reflecting a higher incidence multidrug resistance mechanisms, a low bone marrow reserve which may prevent/delay the recovery of hematopoiesis after treatment, and the occurrence of co-morbidities. Gemtuzumab ozogamicin (GO) is an immunoconjugate with a humanized anti-CD33 that after internalization, releases a cytotoxic drug, calicheamicin; ≥80% of AML pts have myeloid blast cells that express the CD33 surface antigen. GO as a single agent has low antileuk…

Oncologymedicine.medical_specialtyGemtuzumab ozogamicinbusiness.industryImmunologyCombination chemotherapyCell BiologyHematologyHematology myeloid leukemia (AML)BiochemistrySurgeryFludarabineMaintenance therapyInternal medicineCyclosporin amedicineFLAG (chemotherapy)IdarubicinbusinessEtoposidemedicine.drugBlood
researchProduct

Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (…

2010

Abstract Abstract 1360 The arbitrary cut-off of 5000/μL chronic lymphocytic leukemia (CLL)-phenotype cells in peripheral blood is generally used to separate monoclonal B-cell lymphocytosis (MBL) from CLL. However, a major concern is the biological differentiation, if any, between MBL and CLL. We tried to address the issue therefore analyzing 261 Rai stage 0 patients enrolled in a Gruppo Italiano Studio Linfomi (GISL) prospective multicentre trial designed to validate biological parameters in early CLL as well as to assess the impact on clinical outcome of an early versus delayed policy of treatment with subcutaneous alemtuzumab in the high biological risk. In this cohort, biological charact…

Oncologymedicine.medical_specialtyLymphocytosisbusiness.industryChronic lymphocytic leukemiaImmunologyCell BiologyHematologymedicine.diseaseBiochemistryPeripheral bloodhemic and lymphatic diseasesInternal medicineMonoclonalCohortmedicineAlemtuzumabMonoclonal B-cell lymphocytosisStage (cooking)medicine.symptombusinessmedicine.drugBlood
researchProduct

Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG)

2015

Abstract Background: Nucleophosmin (NPM1mut) mutations represent one of the most common gene mutations in acute myeloid leukaemia (AML) and can be used for monitoring minimal residual disease (MRD). In a former study, we could define clinical relevant check-points and a cut-off value to identify patients (pts) at high risk of relapse. Aims: To confirm our previous results on the clinical relevance of NPM1mut transcript levels (TL) in an extended cohort of younger AML pts (18 to 60 years) harbouring NPM1mut type A, B, C, D, JT, 4, QM, NM or KM, and to assess the impact of concurrent FLT3 internal tandem duplications (ITD) and DNMT3A (DNMT3Amut) mutations on NPM1mut TL kinetics. Methods: All …

Oncologymedicine.medical_specialtyNPM1Gemtuzumab ozogamicinbusiness.industryImmunologyContext (language use)Cell BiologyHematologyGene mutationBiochemistryMinimal residual diseaseTransplantationInternal medicinemedicineCytarabineIdarubicinbusinessmedicine.drugBlood
researchProduct

Assessment of Treatment Effects By Measurable Residual Disease Monitoring in NPM1-Mutated AML Patients Randomized for Gemtuzumab-Ozogamicin (GO) with…

2018

Abstract Background: Measurable residual disease (MRD), as determined by quantitation of Nucleophosmin 1-mutated (NPM1mut) transcript levels (TL), provides significant prognostic information independent of other risk factors in patients (pts) with acute myeloid leukemia (AML). This is also addressed by the 2017 European LeukemiaNet (ELN) risk stratification system, which recommends taking into account results from MRD monitoring when selecting the appropriate post-remission therapy. Furthermore, MRD monitoring provides a powerful tool to evaluate treatment effects within clinical trials investigating novel therapies. Aims: To determine the impact of the anti-CD33 immunotoxin Gemtuzumab-Ozog…

Oncologymedicine.medical_specialtyNPM1Gemtuzumab ozogamicinbusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologyHematopoietic stem cell transplantationBiochemistryChemotherapy regimenInternal medicinemedicineCytarabineIdarubicinbusinessEtoposideNeoadjuvant therapymedicine.drugBlood
researchProduct

Towards CEP stable sub two cycle IR pulse compression with bulk material

2010

We demonstrate both experimentally and numerically that self-steepening during propagation in a hollow-fiber followed by linear propagation through glass in the anomalous dispersion enables pulse compression down to 1.9 cycles at 1.8 micron wavelength.

Optical amplifierFemtosecond pulse shapingMaterials sciencebusiness.industryPhysics::OpticsSecond-harmonic generationAstrophysics::Cosmology and Extragalactic AstrophysicsWavelengthOpticsPulse compressionOptoelectronicsHigh harmonic generationHigh Energy Physics::ExperimentbusinessSelf-phase modulationBandwidth-limited pulseFrontiers in Optics 2010/Laser Science XXVI
researchProduct

Amplifier similariton fibre laser with nonlinear spectral compression

2012

We propose and numerically demonstrate a new concept of fibre laser architecture supporting self-similar pulse evolution in the amplifier and nonlinear pulse spectral compression in the passive fibre. The latter process is beneficial for improving the power efficiency as it prevents strong spectral filtering from being highly dissipative.

Optical amplifierFemtosecond pulse shaping[PHYS.PHYS.PHYS-OPTICS] Physics [physics]/Physics [physics]/Optics [physics.optics][PHYS.PHYS.PHYS-OPTICS]Physics [physics]/Physics [physics]/Optics [physics.optics]Materials science[ PHYS.PHYS.PHYS-OPTICS ] Physics [physics]/Physics [physics]/Optics [physics.optics]business.industryAmplifierNonlinear optics01 natural sciences7. Clean energyPulse shaping010309 opticsOpticsFiber laser0103 physical sciencesOptoelectronics010306 general physicsbusinessUltrashort pulseBandwidth-limited pulse
researchProduct

The Peregrine soliton in nonlinear fibre optics

2010

International audience; The Peregrine soliton is a localized nonlinear structure predicted to exist over 25 years ago, but not so far experimentally observed in any physical system. It is of fundamental significance because it is localized in both time and space, and because it defines the limit of a wide class of solutions to the nonlinear Schrödinger equation (NLSE). Here, we use an analytic description of NLSE breather propagation to implement experiments in optical fibre generating femtosecond pulses with strong temporal and spatial localization, and near-ideal temporal Peregrine soliton characteristics. In showing that Peregrine soliton characteristics appear with initial conditions th…

Optical fiberGeneral Physics and Astronomy01 natural sciences010305 fluids & plasmaslaw.inventionOpticsNonlinear fibre optics[NLIN.NLIN-PS]Nonlinear Sciences [physics]/Pattern Formation and Solitons [nlin.PS]law0103 physical sciences[ NLIN.NLIN-PS ] Nonlinear Sciences [physics]/Pattern Formation and Solitons [nlin.PS]Rogue wave010306 general physicsNonlinear Sciences::Pattern Formation and SolitonsPhysics[PHYS.PHYS.PHYS-OPTICS]Physics [physics]/Physics [physics]/Optics [physics.optics][ PHYS.PHYS.PHYS-OPTICS ] Physics [physics]/Physics [physics]/Optics [physics.optics]Spacetimebusiness.industryOptical physicsOptical rogue wavesClassical mechanicsNonlinear Sciences::Exactly Solvable and Integrable SystemsFemtosecondPeregrine solitonbusiness
researchProduct